Literature DB >> 28901533

Characteristics of different mesh types for abdominal wall repair in an experimental model of peritonitis.

R Kaufmann1, A P Jairam1, I M Mulder1,2, Z Wu1,3, J Verhelst1, S Vennix1,2, L J X Giesen1, M C Clahsen-van Groningen4, J Jeekel5, J F Lange1.   

Abstract

BACKGROUND: The use of synthetic mesh to repair a potentially contaminated incisional hernia may lead to higher failure rates. A biological mesh might be considered, but little is known about long-term results. Both biological and synthetic meshes were investigated in an experimental model of peritonitis to assess their characteristics in vivo.
METHODS: Male Wistar rats were randomized into five groups and peritonitis was induced. A mesh was implanted after 24 h. Five meshes were investigated: Permacol™ (cross-linked collagen), Strattice™ (non-cross-linked collagen), XCM Biologic® (non-cross-linked collagen), Omyra® Mesh (condensed polytetrafluoroethylene) and Parietene™ (polypropylene). The rats were killed after either 30, 90 or 180 days. Incorporation and shrinkage of the mesh, adhesion coverage, strength of adhesions and histology were analysed.
RESULTS: Of 135 rats randomized, 18 died from peritonitis. Some 180 days after implantation, both XCM Biologic® and Permacol™ had significantly better incorporation than Strattice™ (P = 0·003 and P = 0·009 respectively). Strattice™ had significantly fewer adhesions than XCM Biologic® (P = 0·001) and Permacol™ (P = 0·020). Thirty days after implantation, Permacol™ had significantly stronger adhesions than Strattice™ (P < 0·001). Shrinkage was most prominent in XCM Biologic® , but no significant difference was found compared with the other meshes. Histological analysis revealed marked differences in foreign body response among all meshes.
CONCLUSION: This experimental study suggested that XCM Biologic® was superior in terms of incorporation, macroscopic mesh infection, and histological parameters such as collagen deposition and neovascularization. There must be sufficient overlap of mesh during placement, as XCM Biologic® showed a high rate of shrinkage. Surgical relevance The use of synthetic mesh to repair a potentially contaminated incisional hernia is not supported unequivocally, and may lead to a higher failure rate. A biological mesh might be considered as an alternative. There are few long-term studies, as these meshes are expensive and rarely used. This study evaluated the use of biological mesh in a contaminated environment, and investigated whether there is an ideal mesh. A new non-cross-linked biological mesh (XCM Biologic® ) was evaluated in this experiment. The new non-cross-linked biological mesh XCM Biologic® performed best and may be useful in patients with a potentially contaminated incisional hernia.
© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28901533     DOI: 10.1002/bjs.10635

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  4 in total

Review 1.  A critical review of the in vitro and in vivo models for the evaluation of anti-infective meshes.

Authors:  O Guillaume; B Pérez Kohler; R Fortelny; H Redl; F Moriarty; R G Richards; D Eglin; A Petter Puchner
Journal:  Hernia       Date:  2018-08-28       Impact factor: 4.739

2.   Extracellular Matrix-Based Biomaterials and Their Influence Upon Cell Behavior.

Authors:  Madeline C Cramer; Stephen F Badylak
Journal:  Ann Biomed Eng       Date:  2019-11-18       Impact factor: 3.934

Review 3.  Systematic review of the stage of innovation of biological mesh for complex or contaminated abdominal wall closure.

Authors:  S K Kamarajah; S J Chapman; J Glasbey; D Morton; N Smart; T Pinkney; A Bhangu
Journal:  BJS Open       Date:  2018-06-14

4.  XCM Biologic Tissue Matrix xenograft and autologous micromucosa graft for vaginal reconstruction in Mayer-Rokitansky-Küster-Hauser syndrome.

Authors:  Tatiana Gigante Gomes; Mariana Agostinho; Mariana Conceição Cardoso; João Nunes da Costa; Júlio Matias
Journal:  Arch Plast Surg       Date:  2021-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.